Immunotherapy for advanced and recurrent malignant pleural mesothelioma

Area of Science:

• Oncology
• Immunotherapy
• Thoracic Cancers

Background:

• Malignant pleural mesothelioma is an aggressive asbestos-related cancer with limited treatment options.
• Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic strategy in various cancers.
• Understanding ICI efficacy in mesothelioma is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the effects of single-agent or combination immune checkpoint inhibitors.
• To assess ICI efficacy in both first-line and salvage treatment settings for advanced malignant pleural mesothelioma.

Main Methods:

• This is a protocol for a Cochrane Review.
• The review will synthesize evidence from relevant clinical trials.
• Systematic review methodology will be employed.

Main Results:

• Results are pending completion of the systematic review.
• The review aims to identify the benefits and harms of ICIs.
• Data synthesis will focus on treatment response and survival.

Conclusions:

• Conclusions will be drawn upon synthesis of the evidence.
• Findings will inform clinical practice guidelines for mesothelioma treatment.
• The review will highlight areas for future research in ICI therapy for mesothelioma.